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hould Microvolt T-Wave
lternans Be Utilized Routinely
n Selecting Patients for
rophylactic Implantable
ardioverter-Defibrillator
nsertion in the Setting
f Ischemic Heart Disease?*
ndrea M. Russo, MD, FACC,
rancis E. Marchlinski, MD, FACC
hiladelphia, Pennsylvania
ost patients who receive implantable cardioverter-
efibrillators (ICDs) for primary prevention never develop
ustained ventricular arrhythmias. In addition, the majority
f patients in the overall population who die suddenly are
ot identified by current methods of risk stratification (1).
jection fraction lacks sufficient sensitivity and specificity to
e useful as a single method of risk stratification (1,2). The
tudy by Chow et al. (3) in this issue of the Journal suggests
hat risk stratification with microvolt T-wave alternans
MTWA) identifies patients who are most and least likely
o benefit from ICD therapy.
See page 50
TWA and risk prediction—arrhythmic events and
otal mortality. Studies have demonstrated a relationship
etween MTWA and the inducibility of ventricular ar-
hythmias during invasive electrophysiologic testing (4,5). A
ecent meta-analysis examining 19 studies (2,608 subjects)
cross a wide range of populations identified MTWA as a
trong predictor of arrhythmic events, and this predictive
alue was seen in patients with ischemic and non-ischemic
eart disease (6). In a prospective multicenter study of
atients potentially eligible for ICD prophylaxis, Bloomfield
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the University of Pennsylvania Health System, Philadelphia, Pennsylvania.M
rs. Russo and Marchlinski participate in clinical device research trials (Medtronic,
uidant, St. Jude) and speaking engagements with honoraria.t al. (7) demonstrated that MTWA can identify high- and
ow-risk groups among patients with ischemic or nonisch-
mic heart disease and left ventricular ejection fraction
LVEF) 40%, with a primary end point of all-cause
ortality or non-fatal sustained ventricular arrhythmias.
ther studies have demonstrated that MTWA can also
redict total mortality in patients with ischemic heart
isease and reduced left ventricular (LV) function without
rior history of arrhythmia (8,9).
TWA and ICD benefit. The current study by Chow
t al. (3) was performed in patients with ischemic cardio-
yopathy and no prior history of ventricular arrhythmias to
ssess whether ICD benefit differs in MTWA non-negative
positive and indeterminate) versus negative subgroups. The
rimary end point of the current study was all-cause
ortality, and secondary end points included cause-specific
ortality and appropriate ICD shocks. The investigators
ound that mortality reduction with the ICD differs by
TWA status. After multivariable adjustment, ICDs were
ssociated with lower all-cause mortality in MTWA non-
egative patients, and this mortality benefit was due largely
o a reduction in arrhythmic mortality. The latter is not
urprising, as ICDs are anticipated to reduce mortality by
educing arrhythmic death. The authors suggest that
TWA may effectively risk-stratify patients with ischemic
ardiomyopathy by identifying subgroups who receive sub-
tantial versus minimal benefit from ICD therapy. The
eported 70% reduction in arrhythmic mortality is similar to
he 62% reduction (from 10% in the conventional therapy
roup to 3.8% in the ICD group, p  0.01) seen in the
ADIT-II (Multicenter Automatic Defibrillator Implan-
ation Trial) substudy analysis (10).
The current report also suggests that as many as one-third
f patients with ischemic heart disease who meet the current
riteria for prophylactic ICD insertion may derive minimal
enefit from device implantation and that these patients
ay be identified by MTWA testing. However, it is unclear
hen to screen patients after infarction and how often to
epeat MWTA testing if the initial test is negative. The
uthors suggest that one option may be to screen patients
nnually, although data on the conversion rate from
TWA negative to non-negative status is lacking and its
rognostic implications are unclear.
urrent study limitations. Although no significant differ-
nces were seen with ICD therapy in the MTWA-negative
roup, only 75 such patients received an ICD. The authors
cknowledge that their study may not have been adequately
owered to detect a statistical difference in outcome in this
ohort. Patients who have MTWA-negative tests have
uch lower arrhythmic rates (7–9). Therefore, a larger
tudy might also have found a significant benefit with ICD
herapy in the MTWA-negative group. In addition, this
as a prospective cohort study, not a randomized prospec-
ive study evaluating the benefit of ICD therapy based on
TWA status. Propensity scores for ICD insertion based
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Editorial Comment January 2/9, 2007:59–61n variables most likely to influence ICD insertion (such as
lectrophysiology testing, QRS duration, and abnormal
olter) were developed for each MTWA cohort. Multiva-
iable analyses that controlled for propensity score, demo-
raphics, and clinical variables were used to evaluate the
egree to which ICDs reduced mortality risk for each
TWA group. As in all cohort studies, the authors
cknowledge that there exists the potential for residual
onfounding factors. In addition, this study evaluated only
atients with ischemic heart disease, and results may not
pply to patients with non-ischemic disease.
ost and reimbursement. If ICDs were inserted in all
atients meeting the MADIT-II (Multicenter Automatic
efibrillator Implantation Trial II) or SCD-HeFT (Sudden
ardiac Death in Heart Failure Trial) study indications, the
ost implications would be substantial. For example, in the
CD-HeFT study, only a limited percentage of patients (5.1%
er year) in the ICD treatment arm received appropriate
hocks for rapid ventricular tachycardia/ventricular fibrillation
uring follow-up (11). Analysis of a model to evaluate treat-
ent strategies for a hypothetical MADIT II-like patient
evealed that risk stratification with MTWA testing would
mprove the cost-effectiveness of ICDs (12). The findings of
he current study would support this hypothesis, as the
umber of patients needed to treat for 2 years with an ICD
o save 1 life would be 9 among MTWA non-negative
atients and 76 among MTWA-negative patients.
onclusions. At present, there is no single test or known
eries of tests that have been prospectively evaluated that
rovide a high predictive value in identifying high- and
ow-risk patients for primary prevention ICD insertion.
nserting ICDs in all patients who currently meet guide-
ines, based on LV function, leads to implantation of devices
n many patients who will never need them. Not only does
his have implications with respect to the cost, but, in
ddition, a realistic assessment of potential adverse events
nd quality of life should be considered.
On the basis of the results of the current study, MWTA
ppears promising in predicting patients who might be most
ikely and least likely to benefit from ICD therapy. Micro-
olt T-wave alternans has utility in predicting risk in diverse
opulations, including patients with coronary artery disease,
onischemic cardiomyopathy, congestive heart failure, and
atients who already have ICDs. Although MWTA testing
as a low specificity and predictive accuracy, there is a high
egative predictive value. Patients with reduced LV func-
ion who are being considered for prophylactic ICD im-
lantation but have a negative MTWA test might avoid, or
t least postpone, ICD insertion.
Because of limitations of the current cohort study, subse-
uent validation in larger cohort studies or future randomized
tudies is definitely needed before MTWA can be used
outinely as a screening test to determine the need for prophy-
actic ICD insertion. Future study should focus on a larger
cale prospective evaluation of MTWA in prediction of ar-
hythmic events and mortality in ICD recipients. Although
Pisk stratification using MTWA could have important impli-
ations with respect to health care policy and reimbursement,
he results of the current study should not be overinterpreted.
dditional prospective data collection must be acquired before
ajor policy decisions are made.
uture study. The role of MTWA testing in selection of
he best candidates for ICD insertion awaits the results of
arge multicenter trials. The MASTER (Microvolt T-wave
lternanS Testing for Risk Stratification) trials are ongoing
nd will evaluate the role of MTWA in predicting risk of
entricular arrhythmias in patients with coronary artery
isease and reduced LV function who are indicated for
rimary prevention ICDs. The objective of the ABCD
Alternans Before Cardioverter Defibrillator) trial is to
emonstrate that MTWA is at least as effective as invasive
lectrophysiologic testing in determining which patients
ith ischemic heart disease are at increased risk for life-
hreatening arrhythmic events. The REFINE (Risk Esti-
ation Following Infarction-Noninvasive Evaluation)
tudy will evaluate the role of MTWA testing in risk
tratification of a lower risk post-MI group with an LVEF
f up to 50%.
Although the results of ongoing trials will add to our
urrent information about the ability of MTWA to predict
vents in ICD patients, they will not answer all questions.
ther non-invasive tools, such as signal averaging, heart
ate variability, and baroreflex sensitivity, have been shown
o have prognostic value in helping to identify high-risk
atients, but these techniques have not become standard in
linical practice owing to low positive predictive values.
agnetic resonance assessment of scar can identify sub-
trate for inducible ventricular tachycardia in patients with
onischemic cardiomyopathy, independent of LVEF, and
ould prove to be a valuable tool for risk assessment (13).
uture studies evaluating the utility of the combined pre-
ictive value of several methods of risk stratification, includ-
ng MTWA, with long-term follow-up in a variety of
atient populations is warranted.
Perhaps one benefit of potentially avoiding ICD insertion
n the negative-MTWA group is that we may increase
esources for newer, yet-to-be-defined populations who may
erive greater benefit. The majority of patients who die
uddenly do not meet current implantation criteria, and
hese patients have not been included in previous primary
revention trials. The average LVEF in survivors of cardiac
rrest in 2 multicenter randomized secondary prevention
rials was 32% and 45% (14,15). In the future, MTWA
ight demonstrate utility in expanding ICD indications to
etter identify newer populations with an LVEF 35% at
ncreased arrhythmic risk.
eprint requests and correspondence: Dr. Andrea M. Russo,
niversity of Pennsylvania Health System, Penn-Presbyterian Med-
cal Center, 4th Floor PHI, 38th and Market Streets, Philadelphia,
ennsylvania 19104. E-mail: andrea.russo@uphs.upenn.edu.
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